



Published in final edited form as:

Diagn Microbiol Infect Dis. 2015 January ; 81(1): 57–59. doi:10.1016/j.diagmicrobio.2014.10.005.

Unmet Diagnostic Needs in Infectious Disease

Anne J. Blaschke^a, Adam L. Hersh^a, Susan E. Beekmann^b, Dilek Ince^b, Philip M. Polgreen^b, and Kimberly E. Hanson^c

^aDepartment of Pediatrics, Division of Pediatric Infectious Diseases, University of Utah, Salt Lake City, UT

^bDepartment of Internal Medicine, Carver College of Medicine, University of Iowa, Iowa City, IA

^cDepartments of Internal Medicine and Pathology, University of Utah, Salt Lake City, UT

Abstract

Accurate diagnosis is critical to providing appropriate care in infectious diseases. New technologies for infectious disease diagnostics are emerging, but gaps remain in test development and availability. The Emerging Infections Network surveyed Infectious Diseases physicians to assess unmet diagnostic needs. Responses reflected the urgent need to identify drug-resistant infections and highlighted the potential for early diagnosis to improve antibiotic stewardship. Information gained from this survey can help inform recommendations for new diagnostic test development in the future.

Keywords

Rapid Diagnostics; Infectious Disease; Unmet diagnostic needs; Survey; Emerging Infections Network

INTRODUCTION

The importance of diagnostic testing in the management of infectious diseases was recently highlighted in the report of the Infectious Diseases Society of America's (IDSA) Diagnostics Task Force¹ report: "Better Tests: Better Care: Improved Diagnostics for Infectious Diseases." Similar sentiments are expressed in the report on Antibiotic Resistance Threats in the United States² from the Centers for Disease Control and Prevention (CDC). A

© 2014 Elsevier Inc. All rights reserved.

Correspondence to be sent to: Anne J. Blaschke, MD, PhD, University of Utah Department of Pediatrics, Division of Pediatric Infectious Diseases, P.O Box 581289, Salt Lake City, UT 84158, (801) 581-6791 (ph), (801) 585-3789 (fax), anne.blaschke@hsc.utah.edu. Alternate Corresponding Author: Kimberly E. Hanson, MD, MHS, University of Utah Department of Pathology, 15 North Medical Drive East, Salt Lake City, UT 84158, (801) 583-2787 ext 3384 (ph), kim.hanson@hsc.utah.edu.

Conflict of Interest

AJB and KEH have collaborated with BioFire Diagnostics, Inc. (Salt Lake City, UT) on federally-funded projects. AJB has intellectual property in and receives royalties from BioFire Diagnostics, Inc. KEH has performed contract work for SanofiPasteur.

Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

number of new diagnostic technologies for infectious diseases (ID) are rapidly emerging: e.g., broad-range PCR, next-generation sequencing and matrix-assisted laser desorption/ionization time of flight (MALDI-TOF) mass spectrometry. The reports from the IDSA and the CDC highlight deficiencies in current diagnostic methods, and call for approval and access to methods that are rapid, available at the point-of-care, use direct-from-specimen analysis and demonstrate high levels of sensitivity and specificity across a wide range of disease syndromes. The importance of syndrome-based panels (e.g. for central nervous system, bloodstream and respiratory tract infections) is highlighted in the IDSA report¹. Both the IDSA and CDC emphasize the critical need for culture-independent testing for specific pathogens and their pattern of susceptibility to antimicrobial agents.

The routine patient contact of participants in the CDC-funded Emerging Infections Network (EIN) provides an opportunity for a direct assessment of current diagnostic needs from the perspective of care at the bedside. We therefore surveyed EIN members regarding their unmet diagnostic needs. The survey results, reported here, have the potential to focus advocacy, regulatory, and public health activities designed to hasten clinical application of emerging diagnostic technologies.

METHODS

The EIN is a network of infectious diseases physicians in North America that was established in 1995 by the CDC to create a provider-based emerging infections sentinel network³. EIN members who receive surveys are physician members of IDSA who are actively involved in the practice of infectious diseases. This survey was sent electronically or via facsimile to all 1,572 physician members in spring 2013.

The survey consisted of brief introductory text and 9 questions (can be viewed at: http://www.int-med.uiowa.edu/Research/EIN/Unmet_Diagnostic_Needs_Query.pdf). All EIN surveys, including this one, include an “opt-out” option which allows members who are not involved in the aspect of infectious disease practice being queried to answer “not applicable”. For this survey, members were able to respond by email that they were not involved in non culture-based diagnostics without answering any specific survey questions.

In the survey, “unmet” needs were defined as testing not available in the respondent’s clinical practice, or circumstances where test results are not available in a clinically meaningful timeframe. Survey respondents were asked to rank in order from 1 (least important) to 6 (greatest need) selected unmet needs. Six syndromes (central nervous system infection, community-acquired pneumonia, febrile neutropenia, infectious diarrhea, culture-negative endocarditis) and six pathogens (drug resistant gram-negative bacilli, methicillin-resistant *Staphylococcus aureus*, drug resistant *Mycobacterium tuberculosis*, molds, influenza and HIV resistance) were specifically listed. Free text answers were encouraged.

Respondents were additionally asked to: consider the potential impact of rapid identification of specific genetic determinants of antimicrobial resistance on their clinical practice (ranked 1–5, no impact to high impact); choose a single test not currently available to them that would be most helpful; score the importance of various test characteristics (i.e. sensitivity

and specificity, turn around time, cost and availability of outcome data supporting test benefits) when choosing a new test (ranked 1–5, not important to highly important); and to delineate required turn-around-times for various tests in terms of clinical utility. Lastly, respondents were asked their opinion regarding whether some infectious diseases diagnostic testing is becoming too complicated to be interpreted by non-infectious diseases physicians and if there should be “stewardship” for particularly complex or expensive tests.

We used descriptive statistics for analysis and Chi-Square Tests to compare proportions. All analyses were conducted using SAS 9.3 (Cary, NC).

RESULTS

A total of 700 respondents (44.5% of EIN physician members) completed the survey; 97 chose the “opt-out” option by indicating that they did not use non-culture-based diagnostics and were excluded. Forty-five percent of respondents estimated that at least 1 out of 4 patients in their practice are immune compromised. Twenty-three percent of respondents were in pediatric practice. As is usual for most EIN surveys, non-respondents were significantly more likely than respondents to have less than 15 years of experience in ID ($p < 0.001$), to have an adult practice ($p < 0.01$) and to work in a community hospital ($p < 0.01$).

Respondents indicated that their most important pathogen-specific unmet diagnostic need was the prompt identification of drug-resistant aerobic gram-negative bacilli (mean score 4.33 out of 5) (Figure 1A). Identification of drug-resistant *M. tuberculosis* had the second-highest score (3.93 out of 5). Additional pathogens mentioned in the open text field included: *Borrelia burgdorferi*, *Clostridium difficile*, *Aspergillus species*, *Coccidioides immitis* and human parechovirus. Respondents felt that rapid detection of extended-spectrum β -lactamase (ESBL) resistance markers, the *Klebsiella pneumoniae* carbapenamase (KPC) or the presence of *mecA* would strongly impact patient care (all with mean scores 4 out of 5).

The clinical syndrome ranked most highly as in need of improved diagnostics was culture-negative endocarditis (mean score 3.90 out of 5). Infectious diarrhea was the second-ranked syndrome (mean score 3.87 out of 5) (Figure 1B). Other syndromes suggested in the free text included: osteomyelitis/septic arthritis, prosthetic joint infections/orthopedic hardware infections and hospital- or ventilator-associated pneumonia.

When asked to choose a single test not currently available to them (not available in their practice, or not invented yet) that would be most helpful, 18% of 451 members providing a response identified pathogen-based testing for respiratory infection (lower and upper respiratory tract); 15% requested testing that could distinguish viral from bacterial infection and another 15% requested testing for antibiotic resistant organisms, including aerobic gram negative bacilli and staphylococci.

Test accuracy and adequate turn-around-time were identified as the most important test characteristics (mean scores 4.72 out of 5 and 4.61 out of 5, respectively) when choosing to use a new diagnostic test. “Adequate” turn-around-time was categorized as < 1 hour for rapid influenza testing (92%), <12 hours for direct detection of bacterial bloodstream

infection (89%) and up to 24 hours for identification of drug resistant TB (86%). The availability of outcome data supporting the benefits of testing was ranked only slightly higher than cost of the testing (4.1 out of 5 vs. 4.07 out of 5).

The majority (67.5%) of respondents felt that some testing is becoming too complex for non-infectious diseases physicians, and 79% believed there should be stewardship for particularly complicated or expensive tests. Forty-six percent of respondents selected multiplex molecular respiratory panels, broad-range PCR testing and antigen-based tests for fungal infection as tests that should be restricted or require prior approval.

DISCUSSION

New technologies have improved our ability to accurately and rapidly diagnose many infections, but the need for additional advancements is increasingly recognized^{1,2}. This survey of practicing ID physicians suggests areas for future test development that mirror expert opinion. In particular, physicians report the need for testing that can enhance our ability to identify drug-resistant organisms and demonstrate an appreciation for judicious use of high-complexity testing through stewardship.

Antibiotic resistant organisms are a serious health threat.² Overuse of antimicrobials contributes to both the rise and persistence of drug resistant organisms, and there is an urgent need for strategies to shorten the duration of multidrug empiric therapy⁴ and to stop unnecessary prescribing. Diagnostic tests that can quickly identify specific pathogens are critical to antibiotic stewardship efforts that seek to promote narrow-spectrum, targeted treatment for infectious illness as opposed to empiric broad-spectrum therapy.⁴⁻⁶ Survey respondents consistently ranked highly the identification of resistant organisms with emphasis on better testing for multidrug resistant aerobic gram-negative bacilli.

An important caveat pertinent to testing for the genes responsible for resistance in gram-negative organisms is the complexity of the resistance mechanisms. The absence of ESBLs, cephalosporinases, and carbapenemases does not preclude beta-lactam resistance as a result of cell wall porin closure and/or activity of efflux pumps.^{7,8} Molecular test development will need to cover a wide range of possible resistance mechanisms, which presents a significant challenge. Rapid phenotypic resistance testing may be an alternative approach. Our respondents did feel that methods that identified ESBL or KPC resistance mechanisms alone would provide useful information even if other mechanisms of resistance were unknown.

In several cases, tests ranked highly as “unmet” needs (for example, rapid resistance testing for staphylococci, testing panel for infectious diarrhea) were actually commercially available or close to receiving FDA approval at the time the survey was given. This suggests that clinicians are not aware of tests that are available or that developed tests desired by clinicians are not available to them in their practice. Lack of availability may be due to the complexity of the testing strategies, the economics of the laboratory or the absence of outcome data that could be used to support adoption of new tests. It is critical that physicians advocate for testing to be implemented locally or that send out mechanisms are available if

they feel that such testing will positively impact patient care. In addition, it is important that laboratories educate physicians about new diagnostic assays that are available.

Testing strategies that utilize new technologies are often more expensive and complex than traditional methods.^{9,10} Physicians are becoming familiar with the concept of “stewardship” (interventions designed to improve appropriate use) as associated with antibiotic use¹¹, and over half of our survey respondents felt that diagnostic testing could benefit from stewardship as well. Diagnostics stewardship could address overuse of testing, guidance regarding test selection and interpretation, and implementation of work-flow that insures that critical results are received and acted on in a timely manner.

An important component of effective stewardship is an evidence base that can be used to guide decisions.¹¹ Outcome and cost-effectiveness data are urgently needed that can impact testing at both the patient and the system level.¹ Survey respondents ranked availability of outcomes data highly as an important characteristic to consider when choosing a new diagnostic test.

Our study has limitations. The opinions of non-respondents, those that opted-out and other physicians not included in the EIN may be different. Although respondents for any EIN survey usually have more years of experience, and a higher percentage of pediatric members usually respond than the comparable percentage of members with adult practices, these differences potentially may bias the results for this survey. Furthermore, the perspectives of physicians in other clinically relevant specialties were not assessed.

As new technologies evolve, it is important to stay focused on developing tests that address unmet needs and that conserve, rather than consume, our resources. The call for tests to identify resistant aerobic gram-negative bacteria reflects the increasing problems of drug-resistant infection and limited antibiotic development. Recognition of the importance of judicious testing through stewardship also parallels increased awareness of rising healthcare costs. Information gained from this survey can help inform recommendations for new diagnostic test development in the future.

Acknowledgments

Funding

This publication was supported by Cooperative Agreement Number 1U50CK000187 from the Centers for Disease Control and Prevention. Its contents are solely the responsibility of the authors and do not necessarily represent the official views of the Centers for Disease Control and Prevention. This work was also supported by a grant from the National Institute of Allergy and Infectious Diseases [grant number K23-AI079401 to AJB]. ALH received funding support from the Centers for Disease Control and Prevention, The Primary Children’s Foundation and Pfizer, Inc.

We appreciate Dr. David Gilbert’s thoughtful comments and editing of the manuscript.

Abbreviations

IDSA	Infectious Diseases Society of America
EIN	Emerging Infections Network

CDC	Centers for Disease Control and Prevention
ESBL	extended-spectrum β -lactamase
KPC	<i>Klebsiella pneumoniae</i> carbapenamase

References

1. Caliendo AM, Gilbert DN, Ginocchio CC, et al. Better Tests, Better Care: Improved Diagnostics for Infectious Diseases. *Clinical Infectious Diseases*. 2013; 57(S3):S139–170. [PubMed: 24200831]
2. Centers for Disease Control. [Accessed February 7, 2014] Antibiotic Resistance Threats in the United States. 2013. <http://www.cdc.gov/drugresistance/threat-report-2013/pdf/ar-threats-2013-508.pdf>
3. Pillai SK, Beekmann SE, Santibanez S, Polgreen PM. The Infectious Diseases Society of America emerging infections network: bridging the gap between clinical infectious diseases and public health. *Clinical infectious diseases: an official publication of the Infectious Diseases Society of America*. Apr; 2014 58(7):991–996. [PubMed: 24403542]
4. Perez KK, Olsen RJ, Musick WL, et al. Integrating rapid pathogen identification and antimicrobial stewardship significantly decreases hospital costs. *Archives of pathology & laboratory medicine*. Sep; 2013 137(9):1247–1254. [PubMed: 23216247]
5. Huang AM, Newton D, Kunapuli A, et al. Impact of rapid organism identification via matrix-assisted laser desorption/ionization time-of-flight combined with antimicrobial stewardship team intervention in adult patients with bacteremia and candidemia. *Clinical infectious diseases: an official publication of the Infectious Diseases Society of America*. Nov; 2013 57(9):1237–1245. [PubMed: 23899684]
6. Bauer KA, West JE, Balada-Llasat JM, Pancholi P, Stevenson KB, Goff DA. An antimicrobial stewardship program's impact with rapid polymerase chain reaction methicillin-resistant *Staphylococcus aureus*/S. aureus blood culture test in patients with S. aureus bacteremia. *Clinical infectious diseases: an official publication of the Infectious Diseases Society of America*. Nov 1; 2010 51(9):1074–1080. [PubMed: 20879856]
7. Bush K. New beta-lactamases in gram-negative bacteria: diversity and impact on the selection of antimicrobial therapy. *Clinical infectious diseases: an official publication of the Infectious Diseases Society of America*. Apr 1; 2001 32(7):1085–1089. [PubMed: 11264037]
8. Paterson DL, Bonomo RA. Extended-spectrum beta-lactamases: a clinical update. *Clinical microbiology reviews*. Oct; 2005 18(4):657–686. [PubMed: 16223952]
9. Fournier PE, Drancourt M, Colson P, Rolain JM, La Scola B, Raoult D. Modern clinical microbiology: new challenges and solutions. *Nature reviews. Microbiology*. Aug; 2013 11(8):574–585.
10. Baron EJ. Implications of new technology for infectious diseases practice. *Clinical infectious diseases: an official publication of the Infectious Diseases Society of America*. Nov 15; 2006 43(10):1318–1323. [PubMed: 17051500]
11. Tamma PD, Cosgrove SE. Antimicrobial stewardship. *Infectious disease clinics of North America*. Mar; 2011 25(1):245–260. [PubMed: 21316003]

Highlights

- New technologies for infectious disease diagnostics are emerging but gaps remain.
- We surveyed Infectious Diseases physicians to assess unmet diagnostic needs.
- New diagnostics to identify drug-resistant organisms are an important unmet need.
- Notable gaps are identification of gram negatives and culture-negative endocarditis
- Testing stewardship could improve appropriate test use.




Figure 1. Rank of Unmet Pathogen and Syndrome-Based Needs

Survey respondents were asked to rank specifically listed unmet pathogen and syndrome-based needs from 1 (least important) to 6 (greatest need).